Table 2 Patient baseline characteristics and serum markers of liver injury stratified by the PNPLA3 rs738409 and TM6SF2 rs58542926 polymorphisms
Baseline characteristics | PNPLA3 rs738409 (Recessive model) | p-value | TM6SF2 rs58542926 (Dominant model) | p-value | ||
|---|---|---|---|---|---|---|
CC-CG (n = 466) | GG (n = 33) | CC (n = 430) | CT-TT (n = 69) | |||
Age (years) | 40 (33–50) | 35 (28–43) | 0.008 | 40 (32–50) | 40 (32–50) | 0.94 |
Male (n, %) | 222 (47.6%) | 17 (51.5%) | 0.80 | 205 (47.7%) | 34 (49.3%) | 0.91 |
BMI | 26.8 (24–30.1) | 27 (24–29.2) | 0.71 | 26.8 (23.9–30) | 26.9 (24.1–29.9) | 0.95 |
HCV-RNA (log10)†| 4.66 (3.8–5.5) | 4.84 (3.9–4.8) | 0.50 | 4.7 (3.8–5.5) | 4.5 (3.5–5.6) | 0.47 |
Serum markers of liver injury | ||||||
ALT (IU/L) | 58 (40–85) | 66 (38.2–111.2) | 0.51 | 58 (39–87) | 64.5 (42–78) | 0.57 |
AST (IU/L) | 56 (39–80) | 59.5 (34.5–112.5) | 0.68 | 55 (39–80) | 60.5 (40.2–93.2) | 0.28 |
Total bilirubin (mg/dL) | 0.8 (0.7–0.9) | 0.8 (0.6–0.9) | 0.97 | 0.8 (0.7–0.9) | 0.8 (0.7–0.9) | 0.99 |